AlphaSpring Capital and Portfolio Companies Shine in the 2026 Future Healthcare 100 Awards

Based on the Multiple Changes in Industry Landscape and Innovation Logic，2026Future Healthcare in the Coming Years100Strong Selection Focuses on "Showcasing, Trading, and Empowering China's Healthcare Innovation Assets"Self2025Year12Since its launch in the month, the selection has received more than1000Each submission document carries a portion of innovative enthusiasm and embodies the upward strength of the industry.

2026Year5Month21Day, the 10th Future Healthcare100The results of the strong selection are fully revealed. Congratulations to Apricot Capital for winning the honor.「2026China Healthcare Industry-Value Investment and Service Institutions50Strong", Xingzhe Capital partner companyAwards are as follows:

"Innovative Pharmaceuticals and Biologics List"TOP100」：ZAIMING, Enovir, Zhip肽 Bio, Grail Bio, Huanma Bio

"Innovative Devices and Intelligent Manufacturing List"TOP100」: BCIFlex, GensKey Medicine, BIO-LINK

"Innovative Health Services and Industry Chain Services List"TOP 100": BIO-LINK

"China's Most Investment-Worthy Enterprises in the Healthcare Industry"50"Strong": GenFleet Therapeutics, BCIFlex

"The Most Innovative Product Technology in China's Medical and Health Industry"50"Strong": Fengkaili

「2026Innovation Strength Ranking of Listed Companies in the Medical and Health IndustryTOP50」: Akeso Biopharma

「2026Ranking of Overseas Strength of Listed Companies in the Medical and Health IndustryTOP50": RemeGen, Guobang Pharmaceutical

Dedicated to becoming the best entrepreneurial partner, Apricot Capital focuses on investing in outstanding early-stage and growth-stage enterprises in the life sciences industry. Its investment projects cover areas such as biopharmaceuticals and medical devices. By leveraging the power of capital, Apricot Capital walks alongside visionary entrepreneurs to address significant unmet clinical needs worldwide. Over the past decade, Apricot Capital has accurately predicted industry trends, standing shoulder to shoulder with top scientists and entrepreneurs, witnessing and driving forward the growth of the industry together.ADCA global surge in the field, the long-accumulated breakthrough of small nucleic acid technology, and the limitless possibilities in the brain-computer interface sector. At its inception, Apricot Capital successfully invested in China's first...PD1The pharmaceutical company Junshi Biosciences has accompanied the growth of Akeso Biopharma, which has created new milestones in China's biopharmaceutical industry; we have incubated Yilian Biotech to make it becomeADCFieldBDTransaction Leader, Empowering Bowang Pharmaceuticals to Achieve Nearly 10 Billion in Two YearsBDThe heavyweight deal; Apricot Capital takes the lead in laying out China's firstTILTherapy Gravel Bio, the first gene therapy company Tianze CloudTech, the firstKRASListed pharmaceutical company GenFleet Therapeutics; in complex antibodies, cell therapy, gene therapy,mRNAIn all cutting-edge innovative fields, the most promising industry pioneers have been heavily invested in, showcasing the strength of China's biotechnology to the world. For ten years, Apricot Capital has consistently empowered through expertise and ecosystem collaboration, continuously building platforms for innovative exchange and injecting long-term momentum into China's biopharmaceuticals industry.

Future Healthcare100The Strong Selection, after ten years of dedication, has become a highly credible and influential innovation selection benchmark in China's healthcare industry. Over the past decade, it has remained deeply rooted in the industry frontline, closely following the innovative development trends in healthcare, continuously refining the evaluation system, and gradually expanding into a comprehensive ecological evaluation system covering innovative enterprises, leading figures, investment and service institutions, industrial empowerment platforms, and innovative technical products. It has completely witnessed and participated in the growth and upgrading of China’s healthcare innovation ecosystem.